@liliyanglab.bsky.social
📤 13
📥 32
📝 28
pinned post!
Can serotonin and SSRIs help T cells kill cancer? Our
@cp-cell.bsky.social
article by Dr. Bo Li, doctoral candidate James Elsten-Brown and their team reports "Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis!"
www.cell.com/cell/fulltex...
loading . . .
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Serotonin transporter (SERT) inhibits CD8 T cell antitumor immunity by depleting intratumoral serotonin. SERT-blocking selective serotonin reuptake inhibitor (SSRI) antidepressants enhance CD8 T cell ...
https://www.cell.com/cell/fulltext/S0092-8674(25)00502-1
6 months ago
1
8
3
Another week, another
#TylerTuesday
! This Tuesday, Tyler is knocking out mesothelin in his tumor models. Good luck, Tyler!
5 months ago
0
1
0
Congrats to PhD CANDIDATE John Zhu for passing his oral qualifying exams today! Proud of you, John!
5 months ago
0
0
0
Guess What Day It Is
#TylerTuesday
5 months ago
0
1
0
Happy
#TylerTuesday
everyone! Hope you're all having a great week🫀
6 months ago
1
1
0
reposted by
Lisa Situ
6 months ago
ICYMI: SSRIs Elevate Intratumoral Serotonin and Enhance Antitumor Immunity, a
#ResearchWatch
summary of a new study by Dr. Bo Li,
@liliyanglab.bsky.social
, and colleagues at
@dgsomucla.bsky.social
@uclastemcell.bsky.social
aacrjournals.org/cdnews/news/...
loading . . .
SSRIs Elevate Intratumoral Serotonin and Enhance Antitumor Immunity
Major Finding: Serotonin transporter depletes intratumoral serotonin which dampens CD8+ T-cell antitumor immunity.Concept: Serotonin transporter inhibition with SSRIs drives T-cell antitumor immunity ...
https://aacrjournals.org/cdnews/news/2431/SSRIs-Elevate-Intratumoral-Serotonin-and-Enhance
0
4
2
It's
#TylerTuesday
!!
6 months ago
0
1
0
Congratulations to Sean Shen for passing his oral qualifying exams and becoming a PhD Candidate! We're proud of you, Sean!
6 months ago
1
1
0
It's
#TylerTuesday
! Last week PhD Candidate Tyler Halladay shared his research on Engineering iPSC-derived gdT cells for solid tumor therapy with his UCLA Pharmacology community. Thanks for being a great representative of our lab, Tyler!
6 months ago
0
1
0
reposted by
et al.
6 months ago
0
0
1
Congrats to Dr. Bo Li and James Elsten-Brown on earning second place in UCLA TDG's
#LABEST2025
poster competition for their work on SERT regulation of serotonin-dependent antitumor immunity, based on their research in
doi.org/10.1016/j.ce...
Way to go, boys!
6 months ago
2
2
1
reposted by
UCLA Broad Stem Cell Research Center
7 months ago
This
#WorldOvarianCancerDay
, we highlight the work of Dr. Sanaz Memarzadeh and Dr. Lili Yang, who have teamed up to develop a novel immunotherapy they hope will transform ovarian cancer treatment. ➡️
bit.ly/3XsEVBS
loading . . .
UCLA researchers unite to develop immunotherapy they hope will transform ovarian cancer treatment
For decades, the story of ovarian cancer treatment has often followed the same pattern: surgery, chemotherapy, recurrence, repeat.This was the grim reality Dr. Sanaz Memarzadeh encountered as a second...
https://bit.ly/3XsEVBS
0
2
1
reposted by
UCLA Broad Stem Cell Research Center
6 months ago
A UCLA study suggests that common antidepressants could enhance the immune system’s ability to fight
#cancer
and suppress tumor growth. Repurposing these existing FDA-approved drugs could speed up the process of bringing new cancer treatments to patients.
stemcell.ucla.edu/news/common-...
loading . . .
Common antidepressants could help the immune system fight cancer, UCLA study finds
A widely used antidepressant drug could help the immune system fight cancer, according to a new UCLA research study.Selective serotonin reuptake inhibitors, or SSRIs, significantly enhanced the abilit...
https://stemcell.ucla.edu/news/common-antidepressants-could-help-immune-system-fight-cancer-ucla-study-finds
2
2
3
reposted by
UCLA Broad Stem Cell Research Center
10 months ago
UCLA researchers led by Dr. Lili Yang have discovered a promising new method to treat myeloid malignancies, a group of blood cancers, using off-the-shelf CAR-NKT cells. Learn more this
#WorldCancerDay
how this study could improve patient outcomes:
bit.ly/4hLW0yf
0
4
1
reposted by
Rio Sugimura
7 months ago
Lili Yang, UCLA leverages the power of hematopoietic stem cells to generate CAR-NKT for immunotherapy Harnessing Stem Cells for Off-The-Shelf CAR-NKT Cell Therapy
1
2
1
reposted by
Cell - a Cell Press journal
6 months ago
Now online! Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
loading . . .
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Serotonin transporter (SERT) inhibits CD8 T cell antitumor immunity by depleting intratumoral serotonin. SERT-blocking selective serotonin reuptake inhibitor (SSRI) antidepressants enhance CD8 T cell antitumor immunity and synergize with anti-PD-1, highlighting SSRIs as potential cancer immunotherapeutics.
http://dlvr.it/TKvZ8v
2
4
3
reposted by
et al.
6 months ago
I’m a very lucky person 👍
add a skeleton here at some point
0
2
1
‼️
@uclaupdates.bsky.social
Reports: Who's the team behind identifying serotonin transporter as a tumor immunotherapy target? Dr. Bo Li leads a team of post-docs, grad students and undergrads in identifying immune checkpoints. And of course our lab manager Jie Huang!
newsroom.ucla.edu/stories/anti...
6 months ago
2
2
2
Can serotonin and SSRIs help T cells kill cancer? Our
@cp-cell.bsky.social
article by Dr. Bo Li, doctoral candidate James Elsten-Brown and their team reports "Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis!"
www.cell.com/cell/fulltex...
loading . . .
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Serotonin transporter (SERT) inhibits CD8 T cell antitumor immunity by depleting intratumoral serotonin. SERT-blocking selective serotonin reuptake inhibitor (SSRI) antidepressants enhance CD8 T cell ...
https://www.cell.com/cell/fulltext/S0092-8674(25)00502-1
6 months ago
1
8
3
Dr. Yan-Ruide Charlie Li and our doctoral students Yichen John Zhu and Yuning Christine Chen cover "The clinical landscape of CAR-engineered unconventional T cells" and the amazing therapeutic potential it holds in their review for
@cp-trendscancer.bsky.social
doi.org/10.1016/j.tr...
loading . . .
Redirecting
https://doi.org/10.1016/j.trecan.2025.03.001
6 months ago
1
3
1
Doctoral students Ying Fang and Yuning Christine Chen and their team discuss the promising "Biological functions and therapeutic applications of human mucosal-associated invariant T cells" in their review for
@biomedcentral.bsky.social
Journal of Biomedical Science
doi.org/10.1186/s129...
loading . . .
Biological functions and therapeutic applications of human mucosal-associated invariant T cells - Journal of Biomedical Science
Mucosal-associated invariant T (MAIT) cells are a unique subset of innate-like T lymphocytes that bridge innate and adaptive immunity. Characterized by their semi-invariant T cell receptor (TCR) and a...
https://doi.org/10.1186/s12929-025-01125-x
6 months ago
0
1
0
Dr. Yan-Ruide Li, Ying Fang, and their amazing teammates report their therapeutic innovations in "Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies" in their article for
@natcomms.nature.com
doi.org/10.1038/s414...
loading . . .
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies - Nature Communications
Yang and colleagues have previously reported a clinically guided culture method to generate allogeneic CAR-NKT cells by engineering human hematopoietic stem and progenitor cells. As potential applicat...
https://doi.org/10.1038/s41467-025-56270-6
6 months ago
0
1
0
Our amazing post-docs and doctoral students have made breakthroughs in "Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture", as shown in
@nature.com
Protocols
doi.org/10.1038/s415...
loading . . .
Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture - Nature Protocols
This protocol describes an ex vivo feeder-free culture method to differentiate genetically engineered hematopoietic stem and progenitor cells into allogeneic CAR-NKT cells for off-the-shelf cancer imm...
https://doi.org/10.1038/s41596-024-01077-w
6 months ago
1
2
0
Exciting developments in the field of CAR-T therapies and the strategies to enhance it. Dr. Yan-Ruide Li and his team walk us through the state of the field and its promising future in their review on "Boosting CAR-T cell therapy through vaccine synergy"
doi.org/10.1016/j.ti...
loading . . .
Redirecting
https://doi.org/10.1016/j.tips.2024.12.004
6 months ago
0
1
0
you reached the end!!
feeds!
log in